Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant ...

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 15 stocks set to explode in 2026. On November 7, 2025, Summit ...

Weakened lung function diagnosis can potentially be achieved sooner in the aging process with increased monitoring.

The full manuscript, titled “Enozertinib is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-small Cell Lung Cancer with EGFR Exon 20 and Atypical Mutations,” is available online at Cancer ...

ORIC Pharmaceuticals announces scientific details of discovery and development of enozertinib: South San Francisco Saturday, November 8, 2025, 13:00 Hrs [IST] ORIC Pharmaceuticals ...

From November 6 to 9, the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO) was held in Kunming, Yunnan. This ...

Investing.com -- Oric Pharmaceuticals Inc (NASDAQ:ORIC) stock rose 1.9% in premarket trading Friday after the company published a peer-reviewed research paper on its cancer drug enozertinib in the ...

In June 2025, BlossomHill Therapeutics conducted a study in patients with locally advanced or metastatic non-small cell lung ...

Akeso, Inc. (HKEX: 9926.HK) is excited to announce that the final Overall Survival (OS) analysis results from the HARMONi-A study, a Phase III study evaluating ivonescimab combined with chemotherapy ...

Subcutaneous therapy could be the future of non–small cell lung cancer (NSCLC) as it would decrease time needed for treatment ...

October brought several updates in the lung cancer field, ranging from notable trial results to patient-centered perspectives ...

Scientific studies also reveal that Indian women are more likely to carry mutations such as EGFR, ALK, and ROS1, which are linked to non-small cell lung carcinoma (NSCLC)—a form of cancer increasingly ...